Novel 1,5-diphenylpyrazole derivatives of the formula (I) in which R.sup.1-R.sup.6 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role. ##STR00001##
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5 -ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17 -tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17 -tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.
Anti-malarial alkyloid compounds have the formula: ##STR00001## wherein R.sub.1-R.sub.11 have various disclosed values or their pharmaceutically acceptable salts, and pharmaceutical compositions containing the same.
Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required.
The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [.alpha.]D=-38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug. ##STR00001##
The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-.beta.-xylopyranoside, quercetin-3-.beta.-glucoside, quercetin-3-.alpha.-arabinopyranoside, 3'-methoxyquercetin-3-.alpha.-xylopyranoside, quercetin-3-O-(6''-p-coumaroyl)-.beta.-galactoside, and quercetin-3-O-(6''-benzoyl)-.beta.-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-.alpha.-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.
A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na.sup.+K.sup.+ATPase activity. In addition, a method for inhibiting the progression or development of breast cancer in vivo by administering either actein or an extract of black cohosh comprising triterpene glycosides and optionally at least one other chemoprotective agent is provided.
Disclosed are betaine and a Lycium chinensis leaf extract and a mixture thereof which are preventive and therapeutic of obesity, and uses thereof. They are found to have prophylactic and therapeutic effects on obesity and obesity-induced metabolic syndrome as evaluated for reductive activity against weight, body fat, total cholesterol, triglyceride, and LDL in humans and in mice. Thus, they can be used as active ingredients in pharmaceutical or health functional food compositions for the prevention and treatment of obesity or obesity-induced metabolic syndrome.
A composition for preventing or treating a viral infection, which includes an ethanol extract of Tetracera scandens as an effective component, is provided. The composition exhibits low toxicity and few side effects and effectively inhibits reverse transcriptase activities to suppress synthesis of DNA, and thus can be useful in preventing or treating infections caused by various kinds of RNA viruses.
Compounds effective in inhibiting replication of Hepatitis C virus (\"HCV\") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Compositions and methods for conferring herbicide resistance to and improving nitrogen utilization of bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a polypeptide that confers resistance or tolerance to herbicidal glutamine synthetase inhibitors are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated polynucleotides corresponding to herbicidal glutamine synthetase inhibitor-resistant polynucleotides are provided. Additionally, polypeptides corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated polynucleotides comprising a variant of SEQ ID NO:1, wherein the variant polynucleotide encodes a polypeptide that is resistant to inhibition by herbicidal glutamine synthetase inhibitor.
Berberine or its salts or derivatives are identified as the active compound for selectively inhibiting lung cancer, potentially without toxic side effects. Berberine is preferably obtained by synthesis or partial synthesis, or is obtained from natural sources, such as Coptis teeta, or other berberine containing plants. Berberine and its derivatives are also active against HIV, and may be a safe new drug for the prevention of AIDS, alone or in combination with other antiviral agents. Composition and method of inhibiting tumor or viral infections and malaria without toxic side effects. A natural composition from the rhizome of Coptis teeta may be used as a safe new drug for the prevention of human breast cancer.
The present invention provides diagnostic methods for predicting the effectiveness of treatment of an hepatocellular carcinoma (HCC) patient with an IGF-1R kinase inhibitor by assessing whether the HCC tumor cells express a high level of AFP, or whether serum levels of AFP protein are high. The present invention also provides diagnostic methods for predicting the effectiveness of treatment of cancer patients with IGF-1R kinase inhibitors, based on a determination of the expression level of IR, IGF-2, IGFBP3 or IGFBP7 in tumor cells, or a 4-gene index calculated using the expression vales for each of these four genes, which can be used to identify tumors that will be sensitive to IGF-1R kinase inhibitors, and also those that will be insensitive. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methods are also provided.
Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition.
The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.
Compounds and methods of treating anti-inflammatory conditions are disclosed.
The present invention relates to a thermolabile caffeine fraction useful for an efficient Agrobacterium-mediated genetic transformation in plant systems to develop desired traits in plant, and a method of preparing said fraction from tea leaves and also, an efficient and cost-effective method of introducing said Agrobacterium-mediated genetic transformation into plant systems using said caffeine fraction of tea leaves.
The present invention relates to a chewing gum formulation that serves as a means for awakening human consciousness and mindfulness to the sensorial subtleties, which in turn strengthens sovereignty such that overall psycho-spirituality is enhanced. More particularly, this invention relates to a dietary supplement consisting of the botanical plant Salvia divinorum as the source substance, including Salvinorin Alpha (A) as its primary active constituent, which is precisely extracted from S. divinorum to achieve a consistent dosing regimen predetermined for standardized efficacies.
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor.
The present invention relates to a composition comprising a bamboo plant extract for the prevention and treatment of inflammatory or blood circulation disease. The extracts from bamboo plant have potent anti-inflammatory activity by inhibiting NO production and circulation-improving activity by inhibiting elastase activity and, healing the wound of vascular endothelial cell, activating u-PA expression and inhibiting PAI-1 expression, lowering cholesterol deposit and inhibiting neointima formation, therefore it can be used as the therapeutics or health care food for treating and preventing inflammatory or blood circulation diseases.
Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or herb mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health functional foods preventive and curative of diabetic peripheral neuropathy.
This invention relates to a pharmaceutical composition and a health functional food for preventing or improving neurodegenerative disorders comprising mixed herb extracts of Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 (w/w). The herb extracts mixed Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 have the synergetic effects on increasing the amount of nerve growth factor in vivo, increasing the neural cell proliferation, promoting the formation of neuritis and enhancing cognitive abilities. Thus, the herb extracts of the present invention may be used for a pharmaceutical composition and a health functional food for preventing or treating neurodegenerative disorders.
The present invention relates to a composition for enhancing immunity through inducing the expression of interferon-.beta. comprising a compound represented by Formulas 1 to 8, or Sophora flavescens extract comprising the same and fractions thereof as an active ingredient, a feed additive, feed composition, pharmaceutical composition, food composition, and over-the-counter (OTC) drug composition comprising the composition, and a method for enhancing immunity through administrating the composition. A composition for inducing the expression of interferon-.beta., comprising a compound represented by Formulas 1 to of the present invention, Sophora flavescens extract comprising the same, or fractions thereof as active ingredient can prevent, alleviate, or treat the diseases that can be prevented or treated by increasing the expression of interferon.
The present invention relates to a composition for preventing or treating dementia containing an extract of Prunus mume (Fructus Mume), and the Prunus mume extract of the present invention has outstanding effects in improving spatial recognition ability and in normalizing hippocampal damage (normalizing ERK phosphorylation, increasing ChAT and normalizing NF-kappa B) induced by chronic vascular brain damage in a vascular dementia animal model, and hence can be used to advantage as a medicinal product for preventing or treating dementia diseases and as a functional health food for preventing or alleviating dementia diseases that accompany vascular brain damage such as vascular dementia.
The diterpenic labdane 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,ha-dimethyl-2-methylene-1-n- aphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone, chemically diagrammed as ##STR00001## inhibits the synthesis of pro-inflammatory cytokines, activates the PPAR-gamma receptor and diminishes nuclear factor kappa B. The compound is useful to treat auto-immune diseases, for organ and tissue transplantation, and to treat immunodeficiency (e.g., AIDS).
Compositions and methods for suppressing the shade-avoidance response of plants and improving plant yield are provided. Compositions of the invention include an early flowering 3 (ELF3) maize gene, the promoter for this gene, an Arabidopsis basic helix-loop-helix transcription factor (bHLH-041), and fragments and variants thereof. The ELF3 promoter sequence is useful for driving expression of polynucleotides of interest in a plant. The ELF3 and bHLH-041 sequences of the invention, or variants and fragments thereof, are provided in expression cassettes for use in manipulating expression of the ELF3 and bHLH-041 genes. By increasing expression of ELF3 and/or suppressing expression of bHLH-041, the methods of the invention provide for altered response of a plant to light quality and suppression of the high-density-invoked survival mode of development. The invention thus provides methods for growing crop plants at high population densities for yield enhancement. Transformed plants having the altered shade-avoidance phenotype of the invention, and seeds of said plants, are also provided.
Ortho methoxy phenolic compounds are provided that include methylenedioxyphenyl ferulate and ferulylproline and derivatives thereof. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating cardiovascular diseases, including hypertension, atherosclerosis, coronary heart disease, angina, stroke, and myocardial infarction, are further provided. The compounds are also useful in reducing low-density lipoprotein oxidation, improving or increasing vasodilation, and reducing plaque destabilization in a subject.
Described herein are compositions that comprise cranberry extract and are potent and low in calories. Methods of preventing or treating infections by administering the described compositions are also provided.
The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
SO-transgenic plants overexpressing or lacking SO activity, having modified tolerance or susceptibility to toxicity of sulfite-producing substances, methods for their production and the use thereof for bioremediation of pollutants, as sentinel plants, for enhancing post-harvest quality of plants, plant tissues and plant products and for therapeutic applications.
Materials derived from cinnamon can be administered orally to humans or animals for the purpose of controlling blood glucose as well improving glucose tolerance. Controlling glucose metabolism is essential for those with impaired glucose metabolism as is the case for those with Type II diabetes where insulin function is not properly functioning. Such administration can also be used for the purpose of enhancing nutrient transport for purposes of athletic performance and controlling bodyweight and body fat levels. Similarly related, such administration can also be used for the purpose of enhancing creatine transport into excitable tissues such as skeletal muscle. The material can be administered as extracts of cinnamon and can be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks.
Methods for identifying one or more amino acid substitutions in an oxalate oxidase (OXOX) variant polypeptide that confer maintained or increased OXOX activity are described herein. Methods and compositions for increasing a plant's resistance to a pathogen using the modified OXOX variant polypeptides are provided. Transformed plants, plant cell, tissues, seed, and expression vectors are also provided.
Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Ligustrum lucidum Ait. of the Oleaceae Family possess estrogenic properties in both ER.alpha.+ and ER.beta.+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and/or uterine cancer, and osteoporosis.
The present invention relates to novel tetraploid Lobularia maritima plants having pigmented flower petals. The present invention also relates to methods for creating novel tetraploid Lobularia maritima plants having pigmented flower petals.
The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the management of inflammatory mucosal diseases of both viral and non-viral origin.
Compositions, functional foods, methods of preparation, and their uses for the treatment of diabetic complications and oxidative stress are provided. The compositions, functional foods, and methods relate to herbal extracts from the rhizome of Curcuma L., Puerariae radix, the root of herb Pueraria lobat, Fructus corni, the fruit of herb Cornus officinalis Sieb Et Zucc, and herb Plantago astiatice L.
An herbal formulation for prevention and treatment of Diabetes and associated complications comprising extracts from selected Indian medicinal herbs Emblica officinalis Gaertn. of the Euphorbiaceae Family, Species of herbs of the Genus Salacia of the of the Celastraceae family, Species Strychnos potatorum L. f. of the Strychnaceae family, Species Vetiveria zizanioides (L.) Nash of the Poaceae family, Species Curcuma longa L. of the Zingiberaceae family, Species of herbs of the Genus Aerva of the Amaranthaceae family, Species of herbs of the Genus Biophytum of the Oxalidaceae family, Species of herbs of the Genus Syzygium of the Myrtaceae family, Species Mangifera indica L. of the Anacardiaceae family, Species of herbs of the Genus Cyclea and/or the Genus Cissampelos of the Menispermaceae family, Species of herbs of the Genus Embelia of the Myrsinaceae family, Species of herbs of the Genus Cyperus of the Cyperaceae family, Species Terminalia chebula (Gaertn.) Retz. of the Combretaceae family, Species Centella asiatica (L.) Urban of the Apiaceae family and/or the Species Strychnos nux-vomica L. of the Strychnaceae family and/or the Species Butea frondosa Koen. ex Roxb. of the Papilionaceae family and/or the Species Acacia catechu (L.f.) WiIId. of the Mimosaceae family, Species Coscinium fenestratum (Gaertn.) Colebr. of the Menispermaceae family and/or the Species of herbs of the Genus Berberis of the Berberidaceae family, and species of herbs of the Genus Zizyphus of the Rhamnaceae family. The invention has associate formulations for different diabetes related complications, which are individually useful in clinical requirements such as improving renal health and preventing renal diseases, preventing diabetic retinopathy and prevention and treatment for oxidative damage to heart and blood vessels. The invention is versatile and can be processed into extracts/concentrates and further pharmacologically modified to tablets or capsules or granules or syrups or herbal health drink or inhalable herbal medicinal preparations or ocular preparations or transdermal absorbable preparations such as ointments/gels or injectable medicine.
This invention relates to a composition and method for controlling blood glucose levels in patients with diabetes. An object of the present invention is to provide new herbal formulations for the treatment of diabetes, especially type 2 diabetes. In particular, the preparation and administration of herbal formulations comprising cinnamon and Gymnema sylvestre extract are described herein. An herbal formulation comprising Gymnema sylvestre extract, cinnamon extract, hydroxypropylcellulose, magnesium stearate, calcium phosphate, gelatine, and iron and titanium oxide exhibited improved control of type 2 diabetes as compared to the placebo group in clinical trials.
A process to prepare a recombined transgenic Zea mays plant or plant cell from a first transgenic Zea mays plant cell, wherein the transgene in the recombinant plant or plant cell has an altered genetic structure relative to the genetic structure of the transgene in the first transgenic plant cell, due to homologous recombination-mediated transgene deletion.
The present invention provides a humanized anti-TNF monoclonal antibody and the use thereof. The humanized anti-TNF monoclonal antibody significantly reduces the immunogenicity of murine-antibody while retaining the ability of antibody to recognize antigen, compared with conservative mouse chimeric antibody. Therefore, safety of the antibody in clinical applications has been improved.
Indole alkaloid derivatives having an opioid receptor agonistic effect, their synthesis, and therapeutic compositions containing these derivatives, and methods of treating conditions with these compounds and therapeutic compositions, are provided.
The use of ozonation has been discovered to increase the lutein extraction from aflatoxin-free corn and for some batches of alfalfa. In addition, the ozonation will substantially decrease any aflatoxin in the plant source. The structure of lutein as indicated by HPLC elution profile and the function of lutein using an antimutagenic activity was shown not to be affected by the ozonation.
The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species. The present invention further contemplates a method for the prophylaxis or treatment of mammalian, animal or avian subjects for inflammatory conditions including chronic or transitory inflammatory conditions or for ameliorating the symptoms of an inflammatory condition by the topical or systemic administration of a macrocyclic diterpene obtainable from a member of the Euphorbiaceae family or botanical or horticultural relatives thereof or a derivative, chemical analogue or chemically synthetic form of the agent. The chemical agent of the present invention may be in the form of a purified compound, mixture of compounds, a precursor form of one or more of the compounds capable of chemical transformation into a therapeutically active agent or be in the form of a chemical fraction, sub-fraction or preparation or extract of the plant.
The subject invention concerns materials and methods for modulating seed size in plants. In one embodiment, seed size is decreased relative to wild type seed by inhibiting or knocking out expression of a sorbitol dehydrogenase (Sdh) gene or the gene product thereof. In another embodiment, seed size is increased relative to wild type seed by increasing expression of an Sdh gene or the gene product thereof. The subject invention also concerns materials and methods for modulating seed number or sugar content in plants. In one embodiment, seed number or sugar content is increased relative to wild type seed by inhibiting or knocking out expression of a sorbitol dehydrogenase (Sdh) gene or the gene product thereof. In another embodiment, seed number or sugar content is decreased relative to wild type seed by increasing expression of an Sdh gene or the gene product thereof.
The disclosure provides a method for isolating the bioactive component of the water-soluble extract of Uncaria tomentosa known as C-MED-100.RTM., comprising (i) precipitating the spray drying carrier from C-MED-100.RTM.; (ii) using the resulting C-MED-100.RTM. to obtain a spotting mixture for thin layer chromatography (TLC); (iii) spotting the C-MED-100.RTM. spotting mixture on pre-run TLC plates and eluting the plates to obtain the fluorescing band with R.sub.f=0.2-0.3; (iv) scraping off the R.sub.f=0.2-0.3 band, eluting it in ammonia and freeze drying the eluted band to form a powder; and (v) extracting the powder with methanol to remove solubilized silica gel, concentrating the methanol solution and crystallizing the concentrated solution to obtain the bioactive component. The isolated bioactive component in vitro is a quinic acid analog, preferably quinic acid lactone. By contrast, the disclosure further shows the isolated bioactive component in vivo is quinic acid, whether as free acid or as a quinic acid salt, including quinic acid ammonium salt. The disclosure then provides for a pharmaceutical composition comprising a pharmaceutically effective amount of the bioactive component and a nontoxic inert carrier or diluent. The pharmaceutical composition and bioactive component may be used to enhance immune competency, treat disorders associated with the immune system, inhibit the inflammatory response, treat disorders associated with the inflammatory response, enhance the anti-tumor response, and treat disorders associated with the response to tumor formation and growth, all in mammals.
Methods of making safe extracts of Curcuma longa L. are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.
Provided are methods for extracting flavor and fragrance materials from natural plant materials, using poly(trimethylene ether) glycol homopolymers and copolymers. The poly(trimethylene ether) glycol homopolymers and copolymers act as solubilizers for essential oils, and can be used to provide compositions having a variety of uses in applications such as cosmetics, personal care products, and industrial cleaning products.
The invention relates to methods of reducing circulating glucose levels with compositions obtained from botanical sources. More specifically, the invention relates to methods of treating individuals whom wish to reduce their circulating glucose levels, particularly individuals having elevated circulating glucose levels, with an extract product of Aframomum melegueta.
Methods for treating Alzheimer's Disease (AD) using modulators of lysosomal activity are described herein. More particularly, methods described herein relate to the use and application of compounds or agents that enhance lysosomal activity for the treatment of AD. In a particular aspect, the method relates to the use and application of compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD. Also described herein are methods and assays for screening to identify compounds or agents that increase the pH of the lysosome and/or increase the overall activity of lysosomal proteases for the treatment of AD.
A novel herbal formulation for the prevention and management of various CHD risk factors including vascular inflammatory process responsible for cardiovascular events comprising a hydro-alcoholic extraction of commiphora mukul, Terminalia arjuna, Inula recemosa and Hippophae rhamonoides with or without known additives.
Use of FGF-2 and Anosmin-1 proteins to predict the histopathology of the lesions of a subject with a demyelinating disease of the central nervous system (CNS) by detecting the amount of such proteins in a sample of isolated biological fluid. Furthermore, the present invention relates to a method for the understanding of the histopathological features of the lesions of a subject with a CNS demyelinating disease a kit to carry out this method. Preferably, the CNS demyelinating disease is multiple sclerosis, and the biological fluid is cerebrospinal fluid (CSF).
According to this invention there a novel herbal formulation for the prevention and management of coronary heart disease and associated CHD risk factors, comprising, preparing a hydromethanolic extract of at least two plants selected from of Withania somnifera, Costus speciosus, Hippophae rhamnoides and Terminalia arjuna at 60-80.degree. C., maintaining the pH of the solution between 7-10, separating the active compounds chromatographically, subjecting the active compounds to the step of molecular characterization.
Expressed Sequence Tags (ESTs) isolated from maize are disclosed. The ESTs provide a unique molecular tool for the targeting and isolation of novel genes for plant protection and improvement. The disclosed ESTs have utility in the development of new strategies for understanding critical plant developmental and metabolic pathways. The disclosed ESTs have particular utility in isolating genes and promoters, identifying and mapping the genes involved in developmental and metabolic pathways, and determining gene function. Sequence homology analyses using the ESTs provided in the present invention, will result in more efficient gene screening for desirable agronomic traits. An expanding database of these select pieces of the plant genomics puzzle will quickly expand the knowledge necessary for subsequent functional validation, a key limitation in current plant biotechnology efforts.
Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Disclosed are novel oxylipins that are derived from .gamma.-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.
Disclosed is a composition for treating or preventing gastroesophageal reflux disease, which includes an organic solvent extract of Lonicerae Flos Thunberg. A fraction of the disclosed extract can be very effectively used for treating, preventing, or improving gastroesophageal reflux disease without side effects.
The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetic complications comprising the extract of Homonoia riparia Lour. or the fraction thereof as an active ingredient. More particularly, the extract of Homonoia riparia Lour. or the fractions thereof of the present invention can inhibit the activity of aldose reductase and the generation of the advanced glycation endproducts, the index of diabetic complications, and have powerful activity of inhibiting diabetic complications with brining the anti-cataract, anti-retinopathy, and anti-neuropathy effect, and have the activity of anti-oxidation as well, so that they can be effectively used as an active ingredient of a pharmaceutical composition for the prevention and treatment of diabetic complications.
The present invention relates to a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma comprising the extract of Decaspermum fruticosum as an active ingredient. The extract of Decaspermum fruticosum of the present invention inhibited the increase of eosinophils in bronchoalveolar lavage fluid of the ovalbumin-induced asthma animal model, had the activity of inhibiting the secretions of immunoglobulin and chemokine (Eotaxin) in bronchoalveolar lavage fluid and blood, and inhibited the secretions of NO and TNF-.alpha. in macrophages. Therefore, the extract of Decaspermum fruticosum of the present invention can be effectively used as an active ingredient of a pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma, and of a health functional food for the prevention and improvement of inflammatory disease or asthma.
The present invention provides for the nucleic acid sequences of plant centromeres. This will permit construction of stably inherited recombinant DNA constructs and minichromosomes which can serve as vectors for the construction of transgenic plant and animal cells.
The objective of the present invention is to provide an antifreeze substance which is suitable for practical use and has excellent antifreeze activity in a safe process flow applicable to food production in a simple, efficient and inexpensive manner. The first method for producing a plant extract containing an antifreeze substance according to the present invention comprises the steps of drying a plant containing the antifreeze substance and extracting the antifreeze substance from the dried plant. The second method for producing a plant extract containing an antifreeze substance according to the present invention comprises the steps of extracting the antifreeze substance from a plant, and treating the obtained extract from the extracting step with an adsorbent.
The present invention provides a pharmaceutical composition for treating skin disorders, including enhancing the healing of wounds for diabetic patients. Specifically, this invention relates to the use of the extracts of Plectranthus amboinicus and Centella asiatica for improving skin disorders, including enhancing the healing of wounds for diabetic patients, and a pharmaceutical composition comprising the extracts of Plectranthus amboinicus and Centella asiatica as well as a wound dressing comprising the same. The invention also provides a method for preparing the crude extract and extract of Plectranthus amboinicus.
Cytochrome b5 (Cb5) is a haem-binding protein located in the endoplasmic reticulum (ER) and the outer mitochondrial membranes of higher eukaryotes. In higher plants, animals, and fungi, the ER resident Cb5 has been shown to play a role in desaturation of acyl CoA fatty acids. Higher plants Cb5 isoforms from plants such as soybean or Arabidopsis are capable of modulating omega-3 desaturation. Co-expression of certain Cb5 isoforms with FAD3 in a host plant results in increased production of seed oil content as well as altered ratio between different fatty acids. It is also disclosed here that overexpression of Yarrowia ACL enzymes in the plastids of a host plant helps boost the synthesis of acetyl CoA, which in turn, may lead to increased synthesis of fatty acids and enhanced oil accumulation in the seeds.
A method of increasing biomass, vigor and/or yield of a plant is disclosed. The method comprises expressing within the plant an exogenous polypeptide comprising a UGGPase activity. The polypeptide may comprise an amino acid sequence at least 90% homologous, and/or at least 80% identical to SEQ ID NO: 33 as determined using the BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters. Polynucleotides encoding same and plants expressing same are also disclosed.
A process is provided for improving sensory properties of essential oils by treatment and incubation with a microbial culture during the extraction process. A method for increasing the patchulol content in essential oil extracted from leaves of Pogostemon cablin is provided, comprising contacting a dried patchouli biomass with microbial cultures, incubating the patchouli biomass under conditions suitable for allowing the increase in the patchulol content and extracting the oil. This process results in increased patchulol content without decreasing the overall oil yields. The patchouli oil also has enriched aroma.
The present invention relates to a process for preparing an extract from ivy leaves which includes the active ingredient hederacoside C and .alpha.-hederin, and to extracts prepared by this process. According to this there is initially provision of a first, .alpha.-hederin-rich extract and subsequently provision of a second, hederacoside C-rich extract. In a last step, the two extracts are blended to give an extract which has an adjusted hederacoside C content and an adjusted .alpha.-hederin content.
Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds.
The present disclosure is relative to a method for the production of Very-Long-Chain Fatty Acids (VLCFA) into a plant cell, including culturing a recombinant plant cell in an appropriate medium, wherein said plant cell is transformed with an heterologous gene encoding for an hydroxyacyl-CoA dehydratase. The disclosure is also relative to a method for producing vegetable oil including high levels of VLCFA.
According to this invention there is provided a herbal formulation for the prevention and management of neurodegenerative disorders comprising, hydro-methanolic extract of at least one plant selected from Curcuma longa, Bacopa monnieri and Valeriana jatamansi, at 70-80.degree. C., maintaining the pH of the solution between 7-10, Separating the active compounds chromatographically and Subjecting the active compounds to the step of molecular characterization.
The invention relates to compounds of formula I ##STR00001## having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
Sunscreen compositions containing an extract of Curcuma longa L. are provided, the sunscreens having an absorption that spans the UVA and UVB ranges in a manner that meets updated FDA recommendations without requiring the addition of titanium dioxide. The sunscreens can also include an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. Microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts in the sunscreens.
The present invention deals with a synergistic herbal composition useful for treatment of rheumatic and musculo-skeletal disorders (RMSDs) comprising a base formulation (50-60%) and plant parts and/or extracts of the plant (40-50%) selected from the group consisting of Withania somnifera, Tribulus terrestris, Phyllanthus emblica and Boswellia serrata optionally along with pharmaceutically acceptable excipients. The herbal formulationis capable of causing simultaneous long term decrease in glycosaminoglycan (GAG) release and aggrecan by cartilage explants resulting in reduction of pain, inflammation, stiffness and low degeneration of bones, joints, muscles and other connective tissues. The present invention further deals with a process for the preparation of the said herbal formulation and a method of treating RMSDs using the formulation up to a high safety level and stable for a long durations.
Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have synergistic effects, with minimal side effects.
The present invention relates to a traditional Chinese medicine composition for preventing and treating swine influenza, preparation method and use thereof. The said traditional Chinese medicine composition is made from Herba Houttuyniae 21.4 wt. %, Caulis Lonicerae Japonicae 17.9 wt. %, Radix Isatidis 14.3 wt. %, Rhizoma Dryopteris Crassirhizomatis 10.7%, Radix et Rhizoma Sophorae Tonkinensis 7.1 wt. %, Radix Angelicae Dahuricae 7.1 wt. %, Rhizoma Paridis 7.1 wt. %, Herba Artemisiae Annuae 7.1 wt. %, and Rhizoma Iridis Tectori 7.1 wt. %.
The present invention provides a method for altering the tryptophan content of a plant by introducing and expressing an isolated DNA segment encoding an anthranilate synthase in the cells of the plant. Transgenic plants transformed with an isolated DNA segment encoding an anthranilate synthase, as well as human or animal food, seeds and progeny derived from these plants, are also provided.
The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.
Provided are methods for treating a hematological malignancy comprising administering an effective amount of flubendazole alone or in combination with a vinca alkaloid. Also provided are compositions and kits comprising an effective amount of flubendazole and/or a vinca alkaloid for use in the methods of the disclosure.
� Copyright©2013. Inventi Journals Pvt.Ltd. All Right Reserved.